Navigation Links
Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
Date:7/4/2008

BASINGSTOKE, England and PHILADELPHIA, July 4 /PRNewswire-FirstCall/ -- Shire Limited (LSE:SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce second quarter 2008 earnings on Thursday 31 July 2008

Results press release will be issued at: 12:00 BST / 07:00 EDT

Investor meeting and conference call time: 14:30 BST / 09:30 EDT

Investor & Analyst meeting and conference call:

Angus Russell, Chief Executive Officer, Graham Hetherington, Chief Financial Officer, Mike Cola, President, Specialty Pharmaceuticals and Sylvie Grégoire, President, Human Genetic Therapies will host the investor and analyst meeting and conference call at 14:30 BST/9:30 EDT.

The meeting will take place at Holborn Bars, 138-142 Holborn, London EC1 2NQ.

Please email claire.rowell@fd.com to register to attend this meeting in London.
The details of the conference call are as follows:

UK and International dial in +44-(0)-203-023-4496

US dial in: +1-866-966-5335

Password/Conf ID: Shire

Live Webcast:

The call will also be available live over the Internet via audio webcast, accessible through http://www.shire.com in the investors section. A slide presentation to accompany the call will also be available on the Shire website.

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details are as follows:

UK and International dial in +44-(0)-208-196-1998

US dial in +1-866-583-1035

Pin code 3008632

Webcast replay: http://www.shire.com, in the investors

section

Notes to Editors

SHIRE LIMITED Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.
For further information please contact:

Investor Relations

Souheil Salah (Rest of the World) +44-1256-894-160

Emily Berish (North America) +1-484-595-8546


'/>"/>
SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... of Directors has approved the payment of a quarterly cash ... The cash dividend of $0.24 per share will ... of record as of the close of business on June ... of the Board of Directors and may be adjusted as ...
(Date:5/23/2016)... May 23, 2016 - Leading CRO,s Use ... - Frontage Implement a Single Platform to Manage End-to-end Operations ... Within the Bioanalytical lab Frontage Laboratories, a full-service contract ... and China , has selected IDBS, ... In addition to serving as the global electronic lab notebook (ELN), ...
(Date:5/23/2016)... Alto, CA (PRWEB) , ... May 23, 2016 ... ... and public interest organization focused on molecular nanotechnology, announced the winners for the ... of pioneer physicist Richard Feynman, are given in two categories, one for experiment ...
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary ... most experienced veterinary clients have treated over 100 of their own patients with the ... provide the highest level of care for their patients. , The veterinarians are ...
Breaking Biology Technology:
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
(Date:3/21/2016)... March 22, 2016 Unique ... passcodes for superior security   ... provider of secure digital communications services, today announced it ... and offer enterprise customers, particularly those in the Financial ... and voice authentication within a mobile app, alongside, and ...
Breaking Biology News(10 mins):